Importace of Elevation of Metallothionein Blood Levels in Patients with Head and Neck Tumors - Part 2

Authors: Z. Horáková 1;  E. Tóthová 1;  R. Salzman 1;  H. Binková 1;  I. Fabrik 2;  P. Smilek 1;  R. Kizek 2
Authors‘ workplace: Klinika otorinolaryngologie a chirurgie hlavy a krku LF MU a FN u sv. Anny, Brno ;  přednosta prof. MUDr. R. Kostřica, CSc. Ústav chemie a biochemie, Agronomická fakulta Mendelovy zemědělské a lesnické univerzity, Brno 1;  přednosta doc. RNDr. P. Hrdlička, CSc. 2
Published in: Otorinolaryng. a Foniat. /Prague/, 57, 2008, No. 2, pp. 90-97.
Category: Comprehensive Reports


Diagnostics of head and neck tumors is far from being easy and most of them are verified in advanced state. One of the reasons might be absence of a reliable diagnostic tumor marker. Authors of the following prospective study evaluated possibility of using methaleothionein as a blood tumor marker. The analysis confirmed significantly elevated level in patients with spinocelullar oropharyngeal carcinoma in comparison with a contol group. MT as diagnostic marker proved to be of a high sinsitivity a specificity. MT level didn’t correlate with any futher tumor characteristics.

Key words:
methaleothionein, oropharyngeal carcinoma, tumor marker.


1. Akcay, F., Taysi, S., Uslu, C., Dogru, Y.: Gümüstekin levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with laryngeal cancor. Japanese Journal of Clinical Oncology, 31, 2001, s. 12-15.

2. Anttonen, A., Leppa, S., Heikkila, P., Grenman, R., Joensuu, H.: Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentratins, Journal of Cancer Research and Clinical Oncology, 10, 2006, s. 1007-1012.

3. Andratschke, M., Chaubal, S., Pauli, C., Mack, B., Hagedorm, H., Wollenberg, B.: Soluble CD 44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer. Anticancer Research, 25, 2005, s. 2821-2826.

4. Bhatavdekar, J., Vora, H., Patel, D.: Serum sialic acid forms as markers for head and neck malignancies. Neoplasma, 35,1988, s. 250-255.

5. Bongers, V., Braaknuis, B. J., Snow G. B.: Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol, 20,1995, s. 479-482.

6. Buntzel, J., Micke, O., Glatzel, M., Frohlich, D., Bruns, F., Mucke, R., Schonekaes, K.: Serum selenium in head and neck cancer patients- A new marker of tumor aktivity. Anticancer Research, 25, 2005, s. 1711-1712.

7. Chow, V., Yuen, A., Lam, K., Ho, W., Wei, W.: Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck, 23, 2001, s. 286-291.

8. Céruse, P., Rabilloud, M., Charrié, A., Dubreuil, C., Disant, F.: Study of cyfra 21-1, a tumor marker in head and neck squamous cell carcinoma. Laryngoskope, 109, 2006, s. 517-523.

9. Doweck, I., Barak, M., Urin, N., Greenberg, E.: The prognostic value of the tumour marker cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. British Journal of Cancor, 83, 2000, s. 1696-1701.

10. Godhale, A., Haddad, R., Cavacini, L., Wirth L. et al.: Serum concentrations of interleukin 8, vascular endothelial growth factor and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol, 41, 2005, s. 70-76.

11. Goumas, P., Mastronikolis, N., Mastrokou, A., Vassilakos, P., Nikiforidis, G.: Evaluation of TATI and cyfra 21-1 in patients with head and neck squamous cell carcinoma, ORL, 59, 1997, s. 106-114.

12. Hajdúch, M., Jarošová, M., Trojanec, R., Indrák, K., Špačková, K., Papajík, T., Cwiertka, K.: Cytogenetické a molekulárně biologické markery v onkologii solidních nádorů a hematologických malignit. Klinická onkologie, suplement, 2004, s. 51-56.

13. Hardisson, D.: Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol, 260, 2003, s. 502-508.

14. Kizek, R., Trnková, L., Paleček, E.: Determination of metallothionein at the femtomole level by constant current stripping chronopotentiometry. Anal. Chem., 73, 2001, s. 4801-4807.

15. Kuratomi, Y., Katayama, M., Kidera, K., Hayashida, S. et al.: Blood concentration of laminin gamma 2 chain in patients with head and neck cancer. Nippon, Saga University (on line) 109, 2006, s. 517-523.

16. Kuropkat, C., Dünne, A. A., Plehn, S., Ossendorf, M., Herz, U., Renz, H., Werner, J. A.: Macrophage colony-stimulating factor as a tumor marker for squamous cell carcinoma of the head and neck, Tumor Biology, 25, 2003, s. 236-240.

17. Kuropkat, C., Lippert, B. M., Werner, J. A.: Follow up with serum cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Oncology, 63, 2002, s. 312-318.

18. Kuropkat, C., Duenne, A. A., Herz, U., Renz, H., Werner, J. A.: Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer, Neoplasma, 51, 2004, s. 51-55.

19. Lara, P., Cuyas, J.: The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Cancer, 76, 1995, s. 758-764.

20. Lee, J. K., Hiseh, J. F., Tsai, S. C., Ho, Y. J. et al.: Comparison of cyfra 21-1 and squamous cell carcinoma antigen in detectin nasopharyngeal carcinoma. Annal of Otology, Rhinology and Laryngology, 110, 2001, s. 775-773.

21. Liu, C., Sheen, T., Ko, J., Shun, C.: Circulating intercellular adhesion molecule 1, E selectin and vascular cell adhesion molecule 1 in head and neck cancer. British Journal of Cancer, 79, 1999, s. 360-362.

22. Malina, R., Torres, M., Moragas, M., Filella, X., Jo, J., Gimonez, N., Traserra, J., Ballesta, A.: Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Anticancer Research, 15, 1995, s. 479-484.

23. Ogawa, T., Tsurusako, Y., Nobuhiko, K., Shinji, N., Akagi, H., Nishizaki, K., Nishioka, K., Rutka, J.: Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngol, suppl., 540, 1999, s. 72-76.

24. Papadimitrakupoulou, B. A., Brown, E. N., Liu, D. D., El Naggar, A. K., Lee, J. J., Hong, W. K., Lee, H. Y.: The prognostic role of loss of insulin like growth factor binding protein 3 expression in head and neck carcinogenesis. Cancer Letters, 239, 2006, s. 136-143.

25. Pectisides, D., Bouzaranis, J., Economides, N., Pozadzidou, P., Gogou, L., Koutsiouba, P.: Squamous cell crcinoma antigen, carcinoembryonic antigen and tumor associated trypsin inhibitor for monitoring head and neck cancer. Int. J. Biol. Markers, 8, 1993, s. 81-87.

26. Riedel, F., Zaiss, I., Herzog, D., Gotte, K., Naim, R., Hormann, K.: Serum levels of interleukin 6 in patiets with primary head and neck squamous cell carcinoma. Anticancer Res., 25, 2005, s. 2761-2765.

27. Soylu, L., Ozcan, C., Cetik, F., Paydas, S., Kiroglu, M. et al.: Serum levels of tumor necrosis factor in squamous cell carcinoma of the head and neck. Am. J. Otolaryngol, 15, 1994, s. 281-285.

28. Strojan, P., Svetic, B., Smid, L., Kos, J.: Serum cystatin C in patients with head and neck carcinoma. Clinica Chimica Acta, 344, 2004, s. 155-161.

29. Strojan, P., Budihna, M., Smid, L., Svetic, B., Vrhovec, I., Skrk J.: Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck, Neoplasma, 48, 2001, s. 66-71.

30. Tartour, E., Deneux, L. Mosseri, V., Jaulerry, C., Brunin, F. et al.: Soluble interleukin 2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study. Cancer, 79, 1997, s. 1401-1408.

31. Vermorken, J.: Medical treatment in head and neck cancer. Annals of Oncology, 16, 2000, s. 258-264.

32. Warawdekar, U., Zingde, S., Iyer, K., Jagannath, P., Mehta, A., Mehta, N.: Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patiens. Clinica Chimica Acta, 372, 2006, s. 83-93.

33. Yen, T. C., Lin, W. Y., Kao, C. H., Cheng K. Y., Wang, S. J.: A study of a new tumour marker, cyfra 21-1 in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin. Otolaryngol, 23, 1998, 1, s. 82-86.

Audiology Paediatric ENT ENT (Otorhinolaryngology)
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account